What question did this study set out to answer?

This paper details the historical and clinical advancements regarding TSH receptor autoantibodies, particularly in Graves’ disease and Hashimoto’s disease.

July 11, 2026Thyroid ResearchOpen Access

TSH receptor autoantibodies – a personal experience

View Full Paper

Ask AI

Bookmark

Authors

BSBernard Rees SmithCardiff University

Discussion

Member takes

Implication

Personal experience illustrates the discovery and therapeutic potential of TSH receptor autoantibodies in thyroid disease, highlighting clinical implications.

Key Points

This paper details the historical and clinical advancements regarding TSH receptor autoantibodies, particularly in Graves’ disease and Hashimoto’s disease.
Discussed the discovery of long acting thyroid stimulator (LATS) and TSH receptor autoantibodies.
Outlined the development of monoclonal autoantibodies including M22™, K1-18™, 5C9™, and K1-70™.
Described cryo-EM analysis used for studying the TSH receptor in complex with monoclonal autoantibodies.
M22™ allowed for crystal structure determination of the TSH receptor, enhancing understanding of its interactions.
K1-70™ has shown beneficial effects in clinical trials for Graves’ hyperthyroidism and Graves’ ophthalmopathy.
Two blocking monoclonal antibodies produced have potential implications for thyroid disease treatment.

Cite This Study

Bernard Rees Smith (2026) studied this question.

synapsesocial.com/papers/6a51dd5ac18d7f28ca4ffeee https://doi.org/10.1186/s13044-026-00309-3

View Full Paper

Ask AI

Bookmark

Implication

Personal experience illustrates the discovery and therapeutic potential of TSH receptor autoantibodies in thyroid disease, highlighting clinical implications.

TSH receptor autoantibodies – a personal experience

Discussion

Member takes

Implication

Key Points

Cite This Study

TSH receptor autoantibodies – a personal experience

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider